Brief: Strides Pharma Science - Stelis Biopharma's Bengaluru Facility Receives EIR From USFDA
18/01/2023 04:42
Jan 18 (Reuters) - Strides Pharma Science Ltd SRID.NS :
* STRIDES PHARMA SCIENCE LTD - STELIS BIOPHARMA'S FACILITY RECEIVES EIR FROM
USFDA
* STRIDES PHARMA SCIENCE LTD - EIR FOR DRUG-DEVICE COMBINATION TO BE
COMMERCIALIZED FROM FACILITY IN BENGALURU
Source text for Eikon: ID:nBSE68Ml2d
Further company coverage: SRID.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Strides Pharma Science
See all newsIndia's Strides Pharma jumps on successful closure of USFDA inspection at Bengaluru facility
Brief: Strides Pharma Science Receives USFDA EIR For Flagship Facility In Bengaluru
Brief: Strides Pharma Science Receives US FDA Establishment Inspection Report For Bengaluru Facility
Brief: Strides Pharma Science June-Quarter Consol Net Profit 1.57 Billion Rupees
Brief: Strides Pharma Science March-Quarter Consol Net Profit 1.27 Billion Rupees